25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Akebia Ther
Buy, Hold or Sell?

Let's analyze Akebia together

I guess you are interested in Akebia Ther. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Akebia Ther. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Akebia Ther

I send you an email if I find something interesting about Akebia Ther.

1. Quick Overview

1.1. Quick analysis of Akebia (30 sec.)










1.2. What can you expect buying and holding a share of Akebia? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.0%

What is your share worth?

Current worth
$-0.23
Expected worth in 1 year
$-0.28
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
$-0.05
Return On Investment
-2.5%

For what price can you sell your share?

Current Price per Share
$2.04
Expected price per share
$1.58 - $2.48
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Akebia (5 min.)




Live pricePrice per Share (EOD)
$2.04
Intrinsic Value Per Share
$-3.25 - $10.18
Total Value Per Share
$-3.48 - $9.95

2.2. Growth of Akebia (5 min.)




Is Akebia growing?

Current yearPrevious yearGrowGrow %
How rich?-$50.4m-$17.8m-$17.6m-49.8%

How much money is Akebia making?

Current yearPrevious yearGrowGrow %
Making money-$11.4m-$12.7m$1.2m11.2%
Net Profit Margin-31.8%-28.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Akebia (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Akebia?

Welcome investor! Akebia's management wants to use your money to grow the business. In return you get a share of Akebia.

First you should know what it really means to hold a share of Akebia. And how you can make/lose money.

Speculation

The Price per Share of Akebia is $2.04. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Akebia.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Akebia, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.23. Based on the TTM, the Book Value Change Per Share is $-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.06 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Akebia.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.09-4.5%-0.05-2.6%-0.07-3.4%-0.22-10.7%-0.18-8.8%
Usd Book Value Change Per Share-0.08-3.7%-0.01-0.6%-0.06-3.0%-0.12-5.8%-0.02-0.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.08-3.7%-0.01-0.6%-0.06-3.0%-0.12-5.8%-0.02-0.9%
Usd Price Per Share1.32-1.35-0.80-2.75-6.39-
Price to Earnings Ratio-3.59-23.63--3.33-2.63--8.59-
Price-to-Total Gains Ratio-17.30-24.77--17.20-41.88--7.72-
Price to Book Ratio-5.71--8.95--2.20-0.33-10.54-
Price-to-Total Gains Ratio-17.30-24.77--17.20-41.88--7.72-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.04
Number of shares490
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.01-0.12
Usd Total Gains Per Share-0.01-0.12
Gains per Quarter (490 shares)-6.16-58.16
Gains per Year (490 shares)-24.66-232.65
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-25-350-233-243
20-49-600-465-476
30-74-850-698-709
40-99-1100-931-942
50-123-1350-1163-1175
60-148-1600-1396-1408
70-173-1850-1629-1641
80-197-2100-1861-1874
90-222-2350-2094-2107
100-247-2600-2327-2340

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%2.018.00.010.0%3.037.00.07.5%3.045.00.06.3%
Book Value Change Per Share2.02.00.050.0%3.09.00.025.0%4.016.00.020.0%11.029.00.027.5%14.032.02.029.2%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.019.05.0%2.00.038.05.0%2.00.046.04.2%
Total Gains per Share2.02.00.050.0%3.09.00.025.0%4.016.00.020.0%11.029.00.027.5%14.032.02.029.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Akebia Ther compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.076-0.013-84%-0.061-20%-0.119+56%-0.019-75%
Book Value Per Share---0.231-0.163-30%-0.082-65%0.508-145%0.724-132%
Current Ratio--1.5241.363+12%1.399+9%1.562-2%4.132-63%
Debt To Asset Ratio--1.2431.161+7%1.075+16%0.869+43%0.647+92%
Debt To Equity Ratio----0%9.165-100%5.670-100%3.562-100%
Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Enterprise Value--64473909.44075561791.680-15%-61149000.285+195%379162424.092-83%1311591784.446-95%
Eps---0.092-0.053-43%-0.070-24%-0.218+138%-0.179+95%
Ev To Ebitda Ratio---4.026-2.556-37%2.126-289%-1.316-67%-10.610+164%
Ev To Sales Ratio--0.4310.526-18%-0.317+174%1.361-68%infnan%
Free Cash Flow Per Share---0.031-0.044+44%-0.087+184%-0.135+342%-0.106+247%
Free Cash Flow To Equity Per Share---0.025-0.014-43%-0.114+358%-0.026+3%-0.010-58%
Gross Profit Margin--1.000-9.357+1036%2.398-58%-0.539+154%0.289+246%
Intrinsic Value_10Y_max--10.179--------
Intrinsic Value_10Y_min---3.254--------
Intrinsic Value_1Y_max---0.108--------
Intrinsic Value_1Y_min---0.410--------
Intrinsic Value_3Y_max--0.535--------
Intrinsic Value_3Y_min---1.166--------
Intrinsic Value_5Y_max--2.215--------
Intrinsic Value_5Y_min---1.845--------
Market Cap445089223.680+35%287998909.440295089791.680-2%174130249.715+65%601029724.092-52%1394147084.446-79%
Net Profit Margin---0.535-0.318-41%-0.280-48%-0.810+51%-15.316+2761%
Operating Margin---0.357-0.232-35%-0.288-19%-0.683+91%-15.464+4226%
Operating Ratio--1.3341.241+7%1.318+1%1.760-24%18.784-93%
Pb Ratio-8.831-55%-5.714-8.950+57%-2.200-61%0.334-1808%10.536-154%
Pe Ratio-5.553-55%-3.59323.633-115%-3.335-7%2.633-236%-8.592+139%
Price Per Share2.040+35%1.3201.353-2%0.798+65%2.755-52%6.390-79%
Price To Free Cash Flow Ratio-16.693-55%-10.801-12.689+17%0.690-1666%-2.945-73%-10.136-6%
Price To Total Gains Ratio-26.735-55%-17.29924.775-170%-17.205-1%41.878-141%-7.724-55%
Quick Ratio--1.0071.072-6%0.900+12%1.214-17%6.041-83%
Return On Assets---0.097-0.053-45%-0.048-51%-0.087-10%-0.092-5%
Return On Equity----0%-0.2340%-0.5300%-0.3870%
Total Gains Per Share---0.076-0.013-84%-0.061-20%-0.119+56%-0.019-75%
Usd Book Value---50402000.000-35499500.000-30%-17809750.000-65%110906050.000-145%157861450.000-132%
Usd Book Value Change Per Share---0.076-0.013-84%-0.061-20%-0.119+56%-0.019-75%
Usd Book Value Per Share---0.231-0.163-30%-0.082-65%0.508-145%0.724-132%
Usd Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Usd Enterprise Value--64473909.44075561791.680-15%-61149000.285+195%379162424.092-83%1311591784.446-95%
Usd Eps---0.092-0.053-43%-0.070-24%-0.218+138%-0.179+95%
Usd Free Cash Flow---6666000.000-9625250.000+44%-18938750.000+184%-29450950.000+342%-23111050.000+247%
Usd Free Cash Flow Per Share---0.031-0.044+44%-0.087+184%-0.135+342%-0.106+247%
Usd Free Cash Flow To Equity Per Share---0.025-0.014-43%-0.114+358%-0.026+3%-0.010-58%
Usd Market Cap445089223.680+35%287998909.440295089791.680-2%174130249.715+65%601029724.092-52%1394147084.446-79%
Usd Price Per Share2.040+35%1.3201.353-2%0.798+65%2.755-52%6.390-79%
Usd Profit---20039000.000-11498000.000-43%-12788500.000-36%-47536750.000+137%-39789075.000+99%
Usd Revenue--37428000.00042469750.000-12%48432250.000-23%58973500.000-37%45819475.150-18%
Usd Total Gains Per Share---0.076-0.013-84%-0.061-20%-0.119+56%-0.019-75%
 EOD+6 -2MRQTTM+7 -29YOY+17 -225Y+21 -1810Y+15 -23

3.3 Fundamental Score

Let's check the fundamental score of Akebia Ther based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.553
Price to Book Ratio (EOD)Between0-1-8.831
Net Profit Margin (MRQ)Greater than0-0.535
Operating Margin (MRQ)Greater than0-0.357
Quick Ratio (MRQ)Greater than11.007
Current Ratio (MRQ)Greater than11.524
Debt to Asset Ratio (MRQ)Less than11.243
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.097
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Akebia Ther based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.869
Ma 20Greater thanMa 501.952
Ma 50Greater thanMa 1001.689
Ma 100Greater thanMa 2001.537
OpenGreater thanClose2.050
Total5/5 (100.0%)

4. In-depth Analysis

4.1 About Akebia Ther

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2024-12-05 11:51:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Akebia earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Akebia to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -53.5% means that $-0.54 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Akebia Ther:

  • The MRQ is -53.5%. The company is making a huge loss. -2
  • The TTM is -31.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-53.5%TTM-31.8%-21.7%
TTM-31.8%YOY-28.0%-3.9%
TTM-31.8%5Y-81.0%+49.2%
5Y-81.0%10Y-1,531.6%+1,450.6%
4.3.1.2. Return on Assets

Shows how efficient Akebia is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Akebia to the Drug Manufacturers - Specialty & Generic industry mean.
  • -9.7% Return on Assets means that Akebia generated $-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Akebia Ther:

  • The MRQ is -9.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -5.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.7%TTM-5.3%-4.4%
TTM-5.3%YOY-4.8%-0.5%
TTM-5.3%5Y-8.7%+3.4%
5Y-8.7%10Y-9.2%+0.5%
4.3.1.3. Return on Equity

Shows how efficient Akebia is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Akebia to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.0% Return on Equity means Akebia generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Akebia Ther:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-23.4%+23.4%
TTM-5Y-53.0%+53.0%
5Y-53.0%10Y-38.7%-14.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Akebia Ther.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Akebia is operating .

  • Measures how much profit Akebia makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Akebia to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of -35.7% means the company generated $-0.36  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Akebia Ther:

  • The MRQ is -35.7%. The company is operating very inefficient. -2
  • The TTM is -23.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-35.7%TTM-23.2%-12.6%
TTM-23.2%YOY-28.8%+5.6%
TTM-23.2%5Y-68.3%+45.1%
5Y-68.3%10Y-1,546.4%+1,478.1%
4.3.2.2. Operating Ratio

Measures how efficient Akebia is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.33 means that the operating costs are $1.33 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Akebia Ther:

  • The MRQ is 1.334. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.241. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.334TTM1.241+0.093
TTM1.241YOY1.318-0.077
TTM1.2415Y1.760-0.518
5Y1.76010Y18.784-17.024
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Akebia Ther.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Akebia is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.52 means the company has $1.52 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Akebia Ther:

  • The MRQ is 1.524. The company is able to pay all its short-term debts. +1
  • The TTM is 1.363. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.524TTM1.363+0.161
TTM1.363YOY1.399-0.037
TTM1.3635Y1.562-0.199
5Y1.56210Y4.132-2.570
4.4.3.2. Quick Ratio

Measures if Akebia is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Akebia to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.01 means the company can pay off $1.01 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Akebia Ther:

  • The MRQ is 1.007. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.072. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.007TTM1.072-0.065
TTM1.072YOY0.900+0.172
TTM1.0725Y1.214-0.142
5Y1.21410Y6.041-4.826
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Akebia Ther.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Akebia assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Akebia to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 1.24 means that Akebia assets are financed with 124.3% credit (debt) and the remaining percentage (100% - 124.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Akebia Ther:

  • The MRQ is 1.243. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 1.161. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.243TTM1.161+0.082
TTM1.161YOY1.075+0.086
TTM1.1615Y0.869+0.292
5Y0.86910Y0.647+0.222
4.5.4.2. Debt to Equity Ratio

Measures if Akebia is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Akebia to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Akebia Ther:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY9.165-9.165
TTM-5Y5.670-5.670
5Y5.67010Y3.562+2.108
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Akebia generates.

  • Above 15 is considered overpriced but always compare Akebia to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -3.59 means the investor is paying $-3.59 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Akebia Ther:

  • The EOD is -5.553. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.593. Based on the earnings, the company is expensive. -2
  • The TTM is 23.633. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD-5.553MRQ-3.593-1.960
MRQ-3.593TTM23.633-27.226
TTM23.633YOY-3.335+26.968
TTM23.6335Y2.633+21.000
5Y2.63310Y-8.592+11.225
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Akebia Ther:

  • The EOD is -16.693. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -10.801. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -12.689. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-16.693MRQ-10.801-5.891
MRQ-10.801TTM-12.689+1.887
TTM-12.689YOY0.690-13.378
TTM-12.6895Y-2.945-9.743
5Y-2.94510Y-10.136+7.191
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Akebia is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Akebia Ther:

  • The EOD is -8.831. Based on the equity, the company is expensive. -2
  • The MRQ is -5.714. Based on the equity, the company is expensive. -2
  • The TTM is -8.950. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.831MRQ-5.714-3.117
MRQ-5.714TTM-8.950+3.236
TTM-8.950YOY-2.200-6.750
TTM-8.9505Y0.334-9.285
5Y0.33410Y10.536-10.202
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Akebia Ther.

4.8.1. Institutions holding Akebia Ther

Institutions are holding 27.369% of the shares of Akebia Ther.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30BlackRock Inc5.33430.0003116384849099259358.3479
2024-09-30Vanguard Group Inc4.61560.0002100702987940358.5599
2024-09-30SATTER MANAGEMENT CO., L.P.2.634512.1745574790600
2024-09-30Geode Capital Management, LLC2.17910.000547544642181724.8095
2024-09-30Renaissance Technologies Corp1.7040.00743717800-197000-5.0322
2024-09-30State Street Corp1.57230.0002343052768328724.8718
2024-09-30Jacobs Levy Equity Management, Inc.0.93230.01042034169-60564-2.8913
2024-09-30Northern Trust Corp0.74940.000416350991198213274.2622
2024-09-30Qube Research & Technologies0.60670.00261323729-420887-24.1249
2024-09-30Morgan Stanley - Brokerage Accounts0.49910.00011088892-437772-28.6751
2024-09-30Connor Clark & Lunn Inv Mgmt Ltd0.47970.006710466916320.0604
2024-09-30Federated Hermes Inc0.39780.002586802127690.32
2024-09-30FMR Inc0.31260.000168203814052925.9514
2024-09-30Charles Schwab Investment Management Inc0.26060.0001568667-2307-0.404
2024-09-30Goldman Sachs Group Inc0.22240.000148526913635139.0782
2024-09-30Bank of New York Mellon Corp0.21530.0001469708-134843-22.3047
2024-09-30Wellington Management Company LLP0.18550.00014047184047180
2024-09-30Nuveen Asset Management, LLC0.17440.000138053500
2024-09-30Barclays PLC0.12520.0001273085200482276.1346
2024-09-30Rhumbline Advisers0.11130.0003242876-4184-1.6935
Total 23.312112.206850862976+11620890+22.8%

4.9.2. Funds holding Akebia Ther

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-11-27iShares Russell 2000 ETF2.78550.01556077431-12698-0.2085
2024-10-31Vanguard Total Stock Mkt Idx Inv2.72490.0006594518800
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr1.1930.004260285900
2024-08-31Fidelity Small Cap Index0.97740.01212132609-40144-1.8476
2024-11-27iShares Russell 2000 Value ETF0.83690.027182585623580.1293
2024-09-30Fidelity Extended Market Index0.51560.00361124932230242.0895
2024-10-31Vanguard Russell 2000 ETF0.43470.0128948403-5916-0.6199
2024-10-31State St Russell Sm/Mid Cp® Indx NL Cl C0.38980.0031850513-42800-4.7912
2024-09-30Federated Hermes MDT Small Cap Growth IS0.37110.211680971300
2024-09-30Federated Hermes MDT SCG Institutional0.37110.2116809713-1-0.0001
2024-10-31State St Russell Sm Cap® Indx SL Cl I0.3490.013176150000
2024-09-30NT R2000 Index Fund - NL0.22920.015000425000420
2024-10-31Schwab Small Cap Index0.22410.012848886300
2024-11-27iShares Micro-Cap ETF0.21940.098947875900
2024-11-26Fidelity Enhanced Small Cap ETF0.21020.084545852000
2024-11-27iShares Core S&P Total US Stock Mkt ETF0.1890.00134124254620.1121
2024-09-30NT R2000 Index Fund - DC - NL - 20.18350.014004044004040
2024-09-30Northern Trust Russell 2000 Value Index0.17790.01923880593880590
2024-09-30NT R2000 Value Index Fund - L0.17790.01913880593880590
2024-10-31iShares Russell 2000 Small-Cap Idx Instl0.17580.013383651-31121-7.5032
Total 12.7360.783827787499+1569728+5.6%

5.3. Insider Transactions

Insiders are holding 2.093% of the shares of Akebia Ther.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-29John P ButlerSELL465701.58
2024-02-29Michel DahanSELL86611.58
2024-02-29Nicole R HadasSELL59741.58
2024-02-27John P ButlerSELL377331.52
2024-02-27Michel DahanSELL107441.52
2024-02-27Nicole R HadasSELL74111.52
2024-02-01John P ButlerSELL464891.68
2024-02-01Steven Keith BurkeSELL243111.68
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets207,142
Total Liabilities257,544
Total Stockholder Equity-50,402
 As reported
Total Liabilities 257,544
Total Stockholder Equity+ -50,402
Total Assets = 207,142

Assets

Total Assets207,142
Total Current Assets100,120
Long-term Assets107,022
Total Current Assets
Cash And Cash Equivalents 34,019
Net Receivables 32,170
Inventory 20,493
Other Current Assets 13,438
Total Current Assets  (as reported)100,120
Total Current Assets  (calculated)100,120
+/-0
Long-term Assets
Property Plant Equipment 11,833
Goodwill 59,044
Intangible Assets 9,011
Long-term Assets Other 27,134
Long-term Assets  (as reported)107,022
Long-term Assets  (calculated)107,022
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities65,709
Long-term Liabilities191,835
Total Stockholder Equity-50,402
Total Current Liabilities
Short-term Debt 5,289
Accounts payable 13,494
Other Current Liabilities 46,926
Total Current Liabilities  (as reported)65,709
Total Current Liabilities  (calculated)65,709
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)191,835
Long-term Liabilities  (calculated)0
+/- 191,835
Total Stockholder Equity
Common Stock2
Retained Earnings -1,655,556
Accumulated Other Comprehensive Income 6
Other Stockholders Equity 1,605,146
Total Stockholder Equity (as reported)-50,402
Total Stockholder Equity (calculated)-50,402
+/-0
Other
Cash and Short Term Investments 34,019
Common Stock Shares Outstanding 210,348
Liabilities and Stockholders Equity 207,142
Net Debt 14,562
Net Working Capital 34,411
Short Long Term Debt Total 48,581



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
2,244
0
0
38,470
34,665
134,028
126,358
120,170
110,995
103,459
155,665
159,588
142,940
221,440
195,635
169,118
300,216
259,256
336,822
338,589
364,247
442,713
413,781
403,826
996,540
890,793
823,528
795,220
771,201
787,719
745,174
676,143
644,139
628,703
611,863
602,267
525,550
535,356
521,804
435,894
351,830
276,858
253,712
234,998
241,703
225,477
220,196
207,142
207,142220,196225,477241,703234,998253,712276,858351,830435,894521,804535,356525,550602,267611,863628,703644,139676,143745,174787,719771,201795,220823,528890,793996,540403,826413,781442,713364,247338,589336,822259,256300,216169,118195,635221,440142,940159,588155,665103,459110,995120,170126,358134,02834,66538,470002,244
   > Total Current Assets 
2,244
1,641
0
38,465
33,431
133,739
126,051
119,840
110,480
102,695
154,962
158,804
141,017
219,530
192,522
165,147
296,321
255,053
332,389
333,938
358,356
436,981
407,417
397,526
468,275
347,233
316,396
299,008
309,533
340,756
449,102
391,000
371,437
365,017
331,076
330,084
272,010
302,687
304,163
237,512
184,949
120,719
118,447
109,602
118,149
112,944
112,097
100,120
100,120112,097112,944118,149109,602118,447120,719184,949237,512304,163302,687272,010330,084331,076365,017371,437391,000449,102340,756309,533299,008316,396347,233468,275397,526407,417436,981358,356333,938332,389255,053296,321165,147192,522219,530141,017158,804154,962102,695110,480119,840126,051133,73933,43138,46501,6412,244
       Cash And Cash Equivalents 
1,641
-1,641
0
24,603
21,215
126,319
95,394
49,668
32,780
27,887
76,248
66,712
49,778
43,439
46,177
65,830
187,335
87,250
125,390
89,599
70,156
158,171
163,526
162,430
104,644
62,741
87,212
122,886
147,449
115,374
245,406
169,286
228,698
252,765
246,992
207,204
149,800
174,562
143,893
144,761
90,466
56,953
53,572
46,529
42,925
41,961
39,499
34,019
34,01939,49941,96142,92546,52953,57256,95390,466144,761143,893174,562149,800207,204246,992252,765228,698169,286245,406115,374147,449122,88687,21262,741104,644162,430163,526158,17170,15689,599125,39087,250187,33565,83046,17743,43949,77866,71276,24827,88732,78049,66895,394126,31921,21524,6030-1,6411,641
       Short-term Investments 
0
3,282
0
13,114
11,341
5,832
28,852
68,670
76,138
72,446
76,541
90,754
88,676
173,586
142,472
95,492
73,008
164,555
195,825
240,106
247,636
234,858
238,597
227,714
216,996
105,297
49,553
22,727
245
245
49,943
99,969
39,992
19,999
0
0
0
0
0
0
0
0
0
0
0
0
83,922
0
083,92200000000000019,99939,99299,96949,94324524522,72749,553105,297216,996227,714238,597234,858247,636240,106195,825164,55573,00895,492142,472173,58688,67690,75476,54172,44676,13868,67028,8525,83211,34113,11403,2820
       Net Receivables 
0
0
0
0
135
119
114
57
48
74
48
14
33,823
0
33,823
33,823
33,823
33,823
0
281
34,216
35,852
132
688
16,666
48,435
28,888
29,654
38,864
104,872
39,115
24,466
26,853
35,233
35,005
49,690
50,875
64,582
81,869
23,094
39,180
17,781
19,572
22,592
39,290
26,620
29,765
32,170
32,17029,76526,62039,29022,59219,57217,78139,18023,09481,86964,58250,87549,69035,00535,23326,85324,46639,115104,87238,86429,65428,88848,43516,66668813235,85234,216281033,82333,82333,82333,823033,82314487448571141191350000
       Other Current Assets 
603
0
0
748
739
1,468
1,691
1,445
1,514
2,288
2,125
1,324
2,563
2,505
3,873
3,825
2,155
3,248
11,174
3,952
6,348
8,100
5,162
6,694
15,724
15,554
28,606
7,754
6,626
8,656
10,035
9,037
14,877
12,214
11,181
39,502
33,140
24,121
42,129
29,618
33,541
25,381
24,398
22,039
20,243
18,831
18,961
13,438
13,43818,96118,83120,24322,03924,39825,38133,54129,61842,12924,12133,14039,50211,18112,21414,8779,03710,0358,6566,6267,75428,60615,55415,7246,6945,1628,1006,3483,95211,1743,2482,1553,8253,8732,5052,5631,3242,1252,2881,5141,4451,6911,46873974800603
   > Long-term Assets 
0
-1,641
0
6
1,234
290
306
330
515
764
703
784
1,923
1,910
3,113
3,971
3,895
4,203
4,433
4,651
5,891
5,732
6,364
6,300
528,265
543,560
507,132
496,212
461,668
446,963
296,072
285,143
272,702
263,686
280,787
272,183
253,540
232,669
217,641
198,382
166,881
156,139
135,265
125,396
123,554
112,533
108,099
107,022
107,022108,099112,533123,554125,396135,265156,139166,881198,382217,641232,669253,540272,183280,787263,686272,702285,143296,072446,963461,668496,212507,132543,560528,2656,3006,3645,7325,8914,6514,4334,2033,8953,9713,1131,9101,9237847037645153303062901,23460-1,6410
       Property Plant Equipment 
0
0
0
6
30
164
181
205
210
404
398
479
540
629
1,832
2,688
2,612
2,904
2,934
3,364
3,617
3,714
3,726
3,808
8,023
41,911
42,127
42,940
39,418
37,881
36,264
34,542
35,498
33,838
32,112
30,388
40,606
39,082
37,529
35,959
34,372
32,774
18,810
17,437
16,045
14,664
13,255
11,833
11,83313,25514,66416,04517,43718,81032,77434,37235,95937,52939,08240,60630,38832,11233,83835,49834,54236,26437,88139,41842,94042,12741,9118,0233,8083,7263,7143,6173,3642,9342,9042,6122,6881,832629540479398404210205181164306000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
59,044
59,044
59,044
59,044
59,044
59,044
59,04459,04459,04459,04459,04459,04455,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,053000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
328,153
318,513
309,413
300,312
291,212
282,112
157,484
151,378
144,170
135,159
126,148
117,138
108,127
99,116
90,106
81,095
72,084
63,074
54,063
45,053
36,042
27,032
18,021
9,011
9,01118,02127,03236,04245,05354,06363,07472,08481,09590,10699,116108,127117,138126,148135,159144,170151,378157,484282,112291,212300,312309,413318,513328,153000000000000000000000000
       Other Assets 
0
0
0
0
1,204
125
125
0
0
360
305
305
1,383
1,281
1,281
1,283
1,283
1,299
1,499
1,287
2,274
2,018
2,638
2,492
137,036
128,083
100,539
97,907
75,985
71,917
47,271
44,170
64,857
39,636
67,474
69,604
640,266
39,418
34,953
26,275
94,483
5,238
3,348
0
0
0
0
0
000003,3485,23894,48326,27534,95339,418640,26669,60467,47439,63664,85744,17047,27171,91775,98597,907100,539128,083137,0362,4922,6382,0182,2741,2871,4991,2991,2831,2831,2811,2811,383305305360001251251,2040000
> Total Liabilities 
769
0
0
2,898
3,910
6,161
4,806
6,556
6,917
8,850
5,913
14,176
11,942
53,678
62,347
68,408
232,096
228,639
279,824
238,714
244,916
245,616
247,857
261,285
360,612
324,414
304,172
327,658
376,444
391,355
374,914
358,181
396,521
414,812
437,232
465,117
449,094
509,240
459,504
422,041
342,488
291,210
280,519
274,420
272,287
252,735
253,950
257,544
257,544253,950252,735272,287274,420280,519291,210342,488422,041459,504509,240449,094465,117437,232414,812396,521358,181374,914391,355376,444327,658304,172324,414360,612261,285247,857245,616244,916238,714279,824228,639232,09668,40862,34753,67811,94214,1765,9138,8506,9176,5564,8066,1613,9102,89800769
   > Total Current Liabilities 
769
0
0
2,898
3,902
6,123
4,770
6,522
6,885
8,841
5,903
14,166
11,868
13,409
20,932
26,139
114,268
133,463
181,591
151,357
144,349
151,419
164,420
177,399
265,693
202,613
185,618
223,148
208,118
214,152
195,774
181,458
187,146
172,679
165,595
189,205
256,493
253,914
233,680
187,965
124,756
82,944
92,184
79,702
99,870
66,487
107,300
65,709
65,709107,30066,48799,87079,70292,18482,944124,756187,965233,680253,914256,493189,205165,595172,679187,146181,458195,774214,152208,118223,148185,618202,613265,693177,399164,420151,419144,349151,357181,591133,463114,26826,13920,93213,40911,86814,1665,9038,8416,8856,5224,7706,1233,9022,89800769
       Short-term Debt 
0
0
0
0
4
4
4
0
0
0
0
0
0
40,000
40,000
40,000
0
5
9
7
987
987
0
0
15,000
4,677
4,780
4,884
4,989
5,096
5,206
5,317
5,286
5,429
5,575
5,723
102,345
102,611
102,580
70,207
36,744
29,160
28,757
12,861
24,039
7,065
7,192
5,289
5,2897,1927,06524,03912,86128,75729,16036,74470,207102,580102,611102,3455,7235,5755,4295,2865,3175,2065,0964,9894,8844,7804,67715,00000987987795040,00040,00040,0000000004440000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
9
7
0
0
0
0
0
4,677
0
0
0
0
0
0
0
0
0
0
97,543
97,848
98,158
65,947
32,000
24,000
24,000
8,000
17,500
0
0
0
00017,5008,00024,00024,00032,00065,94798,15897,84897,54300000000004,6770000079500000000000000000
       Accounts payable 
418
0
0
1,970
714
2,077
1,488
3,032
2,021
4,329
2,412
5,273
2,313
2,415
5,143
8,524
2,039
15,083
10,212
8,705
6,998
17,880
4,795
12,684
42,796
15,226
19,321
64,362
39,217
54,379
29,413
40,403
41,308
30,537
41,984
28,809
33,588
19,466
24,944
19,708
18,021
12,577
11,776
9,038
14,635
11,882
10,107
13,494
13,49410,10711,88214,6359,03811,77612,57718,02119,70824,94419,46633,58828,80941,98430,53741,30840,40329,41354,37939,21764,36219,32115,22642,79612,6844,79517,8806,9988,70510,21215,0832,0398,5245,1432,4152,3135,2732,4124,3292,0213,0321,4882,0777141,97000418
       Other Current Liabilities 
351
0
0
928
3,184
4,042
3,278
3,490
4,864
4,512
3,491
8,893
9,555
10,994
15,789
17,615
30,261
34,272
29,033
21,621
51,454
53,960
81,012
94,616
150,917
133,126
121,201
121,760
124,082
119,791
137,626
117,704
125,338
118,460
106,167
138,981
99,654
121,397
101,109
96,785
66,253
-2,089
8,355
14,507
61,196
46,845
90,001
46,926
46,92690,00146,84561,19614,5078,355-2,08966,25396,785101,109121,39799,654138,981106,167118,460125,338117,704137,626119,791124,082121,760121,201133,126150,91794,61681,01253,96051,45421,62129,03334,27230,26117,61515,78910,9949,5558,8933,4914,5124,8643,4903,2784,0423,18492800351
   > Long-term Liabilities 
0
0
0
0
8
38
36
34
32
9
10
10
74
40,269
41,415
42,269
117,828
95,176
98,233
87,357
100,567
94,197
83,437
83,886
94,919
121,801
118,554
104,510
168,326
177,203
179,140
176,723
209,375
242,133
271,637
275,912
192,601
255,326
225,824
234,076
217,732
208,266
188,335
194,718
172,417
186,248
146,650
191,835
191,835146,650186,248172,417194,718188,335208,266217,732234,076225,824255,326192,601275,912271,637242,133209,375176,723179,140177,203168,326104,510118,554121,80194,91983,88683,43794,197100,56787,35798,23395,176117,82842,26941,41540,26974101093234363880000
       Long term Debt Total 
0
0
0
0
0
7
6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
77,455
77,812
78,228
78,598
98,798
96,607
96,917
97,230
1,820
0
0
0
0
27,056
19,246
0
0
0
0
0
0000019,24627,05600001,82097,23096,91796,60798,79878,59878,22877,81277,4550000000000000000000006700000
       Other Liabilities 
0
0
0
0
0
31
30
34
28
9
10
10
68
40,269
41,415
42,269
117,823
95,176
98,233
87,357
100,567
94,197
83,437
83,886
94,919
90,497
88,485
75,699
64,993
74,924
77,940
76,621
88,376
122,341
152,985
158,425
158,898
222,745
194,091
203,393
158,249
154,552
158,369
0
0
0
0
0
00000158,369154,552158,249203,393194,091222,745158,898158,425152,985122,34188,37676,62177,94074,92464,99375,69988,48590,49794,91983,88683,43794,197100,56787,35798,23395,176117,82342,26941,41540,26968101092834303100000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
102
40,257
41,406
42,262
117,801
95,150
98,209
87,334
100,545
94,176
83,368
2,421
9,637
3,874
3,029
1,752
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000001,7523,0293,8749,6372,42183,36894,176100,54587,33498,20995,150117,80142,26241,40640,257102000000000000
> Total Stockholder Equity
1,475
1,475
0
35,572
30,755
127,867
121,552
113,614
104,078
94,609
149,752
145,412
130,998
167,762
133,288
100,710
68,120
30,617
56,998
99,875
119,331
197,097
165,924
142,541
635,928
566,379
519,356
467,562
394,757
396,364
370,260
317,962
247,618
213,891
174,631
137,150
76,456
26,116
62,300
13,853
9,342
-14,352
-26,807
-39,422
-30,584
-27,258
-33,754
-50,402
-50,402-33,754-27,258-30,584-39,422-26,807-14,3529,34213,85362,30026,11676,456137,150174,631213,891247,618317,962370,260396,364394,757467,562519,356566,379635,928142,541165,924197,097119,33199,87556,99830,61768,120100,710133,288167,762130,998145,412149,75294,609104,078113,614121,552127,86730,75535,57201,4751,475
   Common Stock
0
0
0
0
0
0
0
-120,170
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
1
1
1
1
2
2
2
1
2
2
2
2
2
2
2
2
2
2
2
2222222222212221111111111110000000000000-120,1700000000
   Retained Earnings Total Equity00000-1,595,075-1,579,130-1,552,913000-1,460,351-1,389,673-1,330,129-1,247,091-1,177,511-1,090,511-1,030,552-854,801-794,054-699,571-644,986-586,816-514,395-454,341-428,294-394,225-374,050-386,330-363,196-341,679-297,136-259,274-222,966-187,187-161,389-141,532-122,057-111,368-100,673-90,303-80,955-73,33600000
   Accumulated Other Comprehensive Income 
0
-59,588
0
0
-1
-9
-8
-52
-56
-8
-27
-7
-234
-27
37
-7
-42
-179
-254
-181
-442
-550
-459
-409
-261
-36
23
6
0
-4,189
-9
6
13
9
6
6
6
6
6
6
6
6
6
6
6
6
6
6
666666666666669136-9-4,1890623-36-261-409-459-550-442-181-254-179-42-737-27-234-7-27-8-56-52-8-9-100-59,5880
   Capital Surplus 
0
0
0
0
0
201,203
202,536
204,048
204,969
206,146
271,998
287,113
292,783
355,138
356,217
359,991
365,298
372,475
420,448
486,386
493,823
591,871
594,676
597,290
1,150,583
1,153,230
1,164,318
1,167,126
1,188,810
1,251,164
1,400,820
1,408,466
1,425,115
1,460,971
1,504,752
1,526,815
1,536,800
0
0
0
1,562,247
1,564,770
1,568,260
0
0
0
0
0
000001,568,2601,564,7701,562,2470001,536,8001,526,8151,504,7521,460,9711,425,1151,408,4661,400,8201,251,1641,188,8101,167,1261,164,3181,153,2301,150,583597,290594,676591,871493,823486,386420,448372,475365,298359,991356,217355,138292,783287,113271,998206,146204,969204,048202,536201,20300000
   Treasury Stock0000000000000000000000000000000000-162-162-162-162-161-162-79-21000000
   Other Stockholders Equity 
0
0
0
0
-63,364
-133,827,196
-126,155,068
203,969
204,807
205,985
271,836
286,951
292,621
354,976
356,217
359,991
365,298
372,475
420,448
486,386
493,823
591,871
594,676
597,290
1,150,583
1,153,230
1,164,318
1,167,126
1,188,810
1,255,353
1,400,820
1,408,466
1,425,115
1,460,971
1,504,752
1,526,815
1,536,800
1,548,880
1,555,788
1,559,206
1,562,247
1,564,770
1,568,260
1,570,134
1,578,358
1,599,669
1,601,755
1,605,146
1,605,1461,601,7551,599,6691,578,3581,570,1341,568,2601,564,7701,562,2471,559,2061,555,7881,548,8801,536,8001,526,8151,504,7521,460,9711,425,1151,408,4661,400,8201,255,3531,188,8101,167,1261,164,3181,153,2301,150,583597,290594,676591,871493,823486,386420,448372,475365,298359,991356,217354,976292,621286,951271,836205,985204,807203,969-126,155,068-133,827,196-63,3640000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.